ClinicalTrials.gg
Active, not recruitingNCT01291719Updated Oct 27, 2026

Insulin Balanced Infusion System

An interventional study of glucose and insulin infusions in Hyperglycemia and Diabetes, sponsored by Admetsys Corporation. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Admetsys Corporation · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Hyperglycemia with a site in United States — 29 open to participants now, 38 under way, 1 of them phase 3. Hyperglycemia · United States.

Planned enrollment
141st of 265
40 · median 48
Started
2008
with 24 others
No phase
143 of 316
17 open now
Primary completion
2029-11
later than 34 of 37 live
Registered
122nd of 316
by date

Among the 316 studies in Hyperglycemia with a site in United States, this one is the 141st largest by planned enrollment of the 265 interventional ones that give a count, is one of 25 that started in 2008, is one of 143 with no phase, reaches primary completion later than 34 of the 37 other live ones, and was the 122nd registered.

Hyperglycemia

802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.

Browse Hyperglycemia studies →

Open to participants now

29 of the 316 studies in Hyperglycemia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Hyperglycemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to study the use of a counterbalancing system of glucose and insulin infusion with frequent blood glucose monitoring and combined adaptive algorithm can produce tight glycemic control without hypoglycemia; study to develop a closed loop for use in intensive care units and surgery

Read the detailed description

The study is using an experimental design outpatient with individuals having treatment using an automated closed loop glucose control unit; glucoses are measured every 5 minutes using a intravenous glucose sensor and infusion of glucose and insulin are altered without manual intervention as directed by algorithm

03

Conditions studied

  • Hyperglycemia
  • Diabetes

Keywords

  • closed loop glucose control
  • intensive care glucose control
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • type 1 or type 2 diabetic individuals on insulin ages 21-85 with A1c 7-9.9%
  • glucose at time of study > 150 mg/dl

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • renal or hepatic disease
  • poor intravenous access
  • anemia
  • electrolyte abnormality
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    insulin and glucose infusion

    trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system

    Device: glucose and insulin infusions

Interventions

  • Deviceglucose and insulin infusions

    combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl

06

What researchers measure

Primary outcomes

  1. glucose control in target range

    blood glucose measurements in target range (80-125 mg/dl)

    Time frame: data will be evaluated within 6 months after completion of all 40 studies

Secondary outcomes

  1. hypoglycemia

    blood glucose \<70 mg/dl

    Time frame: data will be evaluated within 6 months after all 40 studies are completed

07

Study locations

1 site
  • 3113 Lawton Road
    Orlando, Florida 32803, United States
08

References and documents

Publications

  • Hashemi N, Valk T, Houlind K, Ejskjaer N. Insulin-Based Infusion System: Preliminary Study. J Diabetes Sci Technol. 2019 Sep;13(5):935-940. doi: 10.1177/1932296818821349. Epub 2019 Jan 24. PubMed 30678470 ↗
  • Hashemi N, Valk T, Houlind K, Ejskjaer N. Insulin-Based Infusion System: Advancing the Development. J Diabetes Sci Technol. 2019 Sep;13(5):941-948. doi: 10.1177/1932296819832876. Epub 2019 Mar 10. PubMed 30854885 ↗

Individual participant data

Plan to share: No — with publication the data will be shared

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Nov 2008, a primary completion of Nov 2029 and a completion of Nov 2029. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Nov 2026 → Nov 2029 and completion Nov 2026 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2011
First posted
Feb 8, 2011
Start
Nov 2008
Primary completionEst.
Nov 2029was Nov 2026
CompletionEst.
Nov 2029was Nov 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Nov 2029
Oct 27, 2026
Study completion
Nov 2026→Nov 2029
Oct 27, 2026
Design
Added Not applicable; removed Phase 1·Phase 2
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Nov 2026→Nov 2029
    Study completion Nov 2026→Nov 2029
    Design Added Not applicable; removed Phase 1·Phase 2
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01291719
Lead sponsor
Admetsys Corporation
Responsible party
Timothy Valk MD (Chief Scientist, Admetsys Corporation) — Principal investigator
First posted
Feb 8, 2011
Start date
Nov 2008
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Timothy W Valk, MD
principal investigator · Admetsys Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion